82 related articles for article (PubMed ID: 11510145)
1. [Study of the antiviral activity, pharmacokinetics and toxic properties of liposomal form of human alpha-2b interferon administered topically].
Zolin VV; Agafonova OA; Kolokol'tsov AA; Danilenko ED; Fedosova LK; Gamaleĭ SG; Omigov VV; Fadina VA; Masycheva VI
Vestn Ross Akad Med Nauk; 2001; (5):27-31. PubMed ID: 11510145
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation, pharmacokinetics and tissue distribution of interferon α-2b liposomes after intramuscular injection to rats.
Li H; Yang L; Cheng G; Wei HY; Zeng Q
Arch Pharm Res; 2011 Jun; 34(6):941-8. PubMed ID: 21725815
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of experimental genital herpes with liposomal interferon].
Mel'nikov VR; Kobrinskiĭ GD; L'vov ND; Bolotin IM; Barinskiĭ IF
Vestn Akad Med Nauk SSSR; 1990; (8):35-7. PubMed ID: 2275275
[TBL] [Abstract][Full Text] [Related]
4. Treatment of experimental genital herpes with liposomal interferon.
Kobrinskii GD; Mel'nikov VR; Kulakov VN; L'vov ND; Bolotin IM; Barinskii IF
Biomed Sci; 1991; 2(1):29-32. PubMed ID: 1912245
[TBL] [Abstract][Full Text] [Related]
5. New treatment of viral genital lesions with low dosage of interferon alpha by oropharyngeal absorption.
Bastianelli C; Caruso MT; Marcellini GF
Clin Ter; 2000; 151(1 Suppl 1):23-8. PubMed ID: 10876963
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics, tissue distribution, excretion, and antiviral activity of pegylated recombinant human consensus interferon-α variant in monkeys, rats and guinea pigs.
Cai Y; Zhang Z; Fan K; Zhang J; Shen W; Li M; Si D; Luo H; Zeng Y; Fu P; Liu C
Regul Pept; 2012 Jan; 173(1-3):74-81. PubMed ID: 21985916
[TBL] [Abstract][Full Text] [Related]
7. [The combined treatment of experimental genital herpes with preparations of interferon and acycloguanosine administered systemically and locally].
Mel'nikov VR; Kobrinskiĭ GD; Lidak MIu; Barinskiĭ IF
Vopr Virusol; 1993; 38(2):69-71. PubMed ID: 8059524
[TBL] [Abstract][Full Text] [Related]
8. In vivo sustained dermal delivery and pharmacokinetics of interferon alpha in biphasic vesicles after topical application.
King M; Kumar P; Michel D; Batta R; Foldvari M
Eur J Pharm Biopharm; 2013 Aug; 84(3):532-9. PubMed ID: 23500117
[TBL] [Abstract][Full Text] [Related]
9. Liposome associated interferon-alpha-2b functions as an anti-fibrogenic factor in dermal wounds in the guinea pig.
Ghahary A; Tredget EE; Shen Q; Kilani RT; Scott PG; Takeuchi M
Mol Cell Biochem; 2000 May; 208(1-2):129-37. PubMed ID: 10939636
[TBL] [Abstract][Full Text] [Related]
10. Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis c: a randomized, controlled study.
Bruno R; Sacchi P; Ciappina V; Zochetti C; Patruno S; Maiocchi L; Filice G
Antivir Ther; 2004 Aug; 9(4):491-7. PubMed ID: 15456079
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of genital herpes with alfa-2b interferon].
Granados Loarca EA; Estrada Barrondo EA
Actas Urol Esp; 2000 May; 24(5):388-92. PubMed ID: 10965574
[TBL] [Abstract][Full Text] [Related]
12. Biological evaluation of Wratizolin penetration from ointments to the skin.
Inglot AD; Mulczyk M; Oleszak E
Arch Immunol Ther Exp (Warsz); 1983; 31(5):631-40. PubMed ID: 6687108
[TBL] [Abstract][Full Text] [Related]
13. Protein spherulites for sustained release of interferon: preparation, characterization and in vivo evaluation.
Jiang Y; Shi K; Xia D; Wang S; Song T; Cui F
J Pharm Sci; 2011 May; 100(5):1913-22. PubMed ID: 21374623
[TBL] [Abstract][Full Text] [Related]
14. Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice.
Morçöl T; Weidner JM; Mehta A; Bell SJD; Block T
AAPS PharmSciTech; 2018 Jan; 19(1):395-412. PubMed ID: 28752471
[TBL] [Abstract][Full Text] [Related]
15. Basis for dosing time-dependent changes in the antiviral activity of interferon-alpha in mice.
Ohdo S; Wang DS; Koyanagi S; Takane H; Inoue K; Aramaki H; Yukawa E; Higuchi S
J Pharmacol Exp Ther; 2000 Aug; 294(2):488-93. PubMed ID: 10900223
[TBL] [Abstract][Full Text] [Related]
16. Research in simple blind with natural interferon alpha at low dosage on subjects affected by labialis and genitalis herpes simplex.
Scalvenzi M; Ceddia C
Clin Ter; 2000; 151(1 Suppl 1):13-8. PubMed ID: 10876961
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the in vitro host range of recombinant met-interferon-con1, interferon-alpha 2b, and interferon-beta [corrected].
Hu CJ; Ozes ON; Klein SB; Blatt LM; Taylor MW
J Interferon Cytokine Res; 1995 Mar; 15(3):231-4. PubMed ID: 7584668
[TBL] [Abstract][Full Text] [Related]
18. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).
Reddy KR
Semin Liver Dis; 2004; 24 Suppl 2():33-8. PubMed ID: 15346244
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of antiviral activity of new medicinal forms of foscarnet in genital herpes in guinea pigs].
Alimbarova LM; Barinskiĭ IF; Kuz'min KK
Vopr Virusol; 1998; 43(2):82-6. PubMed ID: 9606877
[TBL] [Abstract][Full Text] [Related]
20. [The antiviral activity of a number of Soviet chemical preparations and the interferon inducer larifan and their combinations in a model of experimental genital herpes in guinea pigs].
L'vov ND; Samoĭlovich EO; Tikhonchuk IA; Vanag AI; Lidak MIu; Chepaĭkina TA; Tsvetkov EN; Barinskiĭ IF
Vopr Virusol; 1990; 35(4):338-42. PubMed ID: 2256320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
